Sintilimab Combined With Lenvatinib Versus HAIC for Perioperative Treatment of Resectable Primary Hepatocellular Carcinoma

NCT05519410 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

60

Enrollment

OTHER

Sponsor class

Conditions

Resectable Hepatocellular Carcinoma

Interventions

DRUG: Sintilimab and Lenvatinib
DRUG: HAIC-FOLFOX

Sponsor

Tianjin Medical University Cancer Institute and Hospital